2-methoxyphenylmetyrapone profile

2-methoxyphenylmetyrapone: structure given in first source; inhibits cytochrome P-450 11-beta-hydroxylase [MeSH]

ID Source	ID
PubMed CID	10015235
MeSH ID	M0269090

ID Source

PubMed CID

10015235

MeSH ID

M0269090

Synonym
2-methoxyphenylmetyrapone
1-(2-methoxyphenyl)-2-methyl-2-pyridin-3-ylpropan-1-one
1-(2-methoxyphenyl)-2-methyl-2-(3-pyridyl)-1-propanone

Synonym

2-methoxyphenylmetyrapone

1-(2-methoxyphenyl)-2-methyl-2-pyridin-3-ylpropan-1-one

1-(2-methoxyphenyl)-2-methyl-2-(3-pyridyl)-1-propanone

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, This Drug (%)

All Drugs %

pre-1990

0 (0.00)

18.7374

1990's

4 (100.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%

Publication Type

This drug (%)

All Drugs (%)

Trials

0 (0.00%)

5.53%

Reviews

0 (0.00%)

6.00%

Case Studies

0 (0.00%)

4.05%

Observational

0 (0.00%)

0.25%

Other

5 (100.00%)

84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
metyrapone	4	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor	1995	1997	27.8	high	0	0	4	0	0	0

Substance

Studies

Classes

Roles

First Year

Last Year

Average Age

Relationship Strength

Trials

pre-1990

1990's

2000's

2010's

post-2020

metyrapone

aromatic ketone

antimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor

1995

1997

27.8

high

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
Adrenal Gland Diseases	0	2	1995	1996	28.5	high	0	0	2	0	0	0
Sensitivity and Specificity	0	1	1997	1997	27.0	high	0	0	1	0	0	0

Condition

Indicated

Studies

First Year

Last Year

Average Age

Relationship Strength

Trials

pre-1990

1990's

2000's

2010's

post-2020

Adrenal Gland Diseases

1995

1996

28.5

high

Sensitivity and Specificity

1997

27.0

high

Urinary metabolic profile in rat of 1-(2-methoxyphenyl)-2-methyl-2-(3-pyridyl)-1-propanone: a potential radioligand for functional diagnosis of adrenal pathology.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 26, Issue:2, 1996

Metabolic and pharmacokinetic considerations in the design of 2-phenyl substituted metyrapone derivatives: 2-methoxyphenylmetyrapone as a radioligand for functional diagnosis of adrenal pathology.
Nuclear medicine and biology, , Volume: 22, Issue:8, 1995

Article	Year
Pharmacokinetics of 2-methoxyphenylmetyrapone and 2-bromophenylmetyrapone in rats. European journal of drug metabolism and pharmacokinetics, , Volume: 24, Issue:1

Article

Year

Pharmacokinetics of 2-methoxyphenylmetyrapone and 2-bromophenylmetyrapone in rats.
European journal of drug metabolism and pharmacokinetics, , Volume: 24, Issue:1

Article	Year
Spectral and chromatographic properties of 2-methoxyphenylmetyrapone and its potential metabolites. Journal of pharmaceutical and biomedical analysis, , Volume: 15, Issue:4	1997

Article

Year

Spectral and chromatographic properties of 2-methoxyphenylmetyrapone and its potential metabolites.
Journal of pharmaceutical and biomedical analysis, , Volume: 15, Issue:4

1997

2-methoxyphenylmetyrapone

Description

Cross-References

Synonyms (3)

Research

Studies (4)

Study Types

Pharmacokinetics (1)

Dosage (1)

2-methoxyphenylmetyrapone

Description

Cross-References

Synonyms (3)

Research

Studies (4)

Study Types

Related Drugs (1)

Drugs Researched Together (1)

Related Conditions (2)

Pharmacokinetics (1)

Dosage (1)